These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9310283)

  • 1. Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group.
    Keefer MC; Wolff M; Gorse GJ; Graham BS; Corey L; Clements-Mann ML; Verani-Ketter N; Erb S; Smith CM; Belshe RB; Wagner LJ; McElrath MJ; Schwartz DH; Fast P
    AIDS Res Hum Retroviruses; 1997 Sep; 13(14):1163-77. PubMed ID: 9310283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group.
    Keefer MC; Graham BS; McElrath MJ; Matthews TJ; Stablein DM; Corey L; Wright PF; Lawrence D; Fast PE; Weinhold K; Hsieh RH; Chernoff D; Dekker C; Dolin R
    AIDS Res Hum Retroviruses; 1996 May; 12(8):683-93. PubMed ID: 8744579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials.
    Gilbert PB; Chiu YL; Allen M; Lawrence DN; Chapdu C; Israel H; Holman D; Keefer MC; Wolff M; Frey SE;
    Vaccine; 2003 Jun; 21(21-22):2933-47. PubMed ID: 12798637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety profile of HIV vaccination: first 1000 volunteers of AIDS vaccine evaluation group. NIAID AIDS Vaccine Clinical Trials Network.
    Keefer MC; Belshe R; Graham B; McElrath J; Clements ML; Sposto R; Fast P
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S139-40. PubMed ID: 7865288
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group.
    Graham BS; Keefer MC; McElrath MJ; Gorse GJ; Schwartz DH; Weinhold K; Matthews TJ; Esterlitz JR; Sinangil F; Fast PE
    Ann Intern Med; 1996 Aug; 125(4):270-9. PubMed ID: 8678389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.
    Keefer MC; Graham BS; Belshe RB; Schwartz D; Corey L; Bolognesi DP; Stablein DM; Montefiori DC; McElrath MJ; Clements ML
    AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1713-23. PubMed ID: 7888231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers.
    Ramanathan VD; Kumar M; Mahalingam J; Sathyamoorthy P; Narayanan PR; Solomon S; Panicali D; Chakrabarty S; Cox J; Sayeed E; Ackland J; Verlinde C; Vooijs D; Loughran K; Barin B; Lombardo A; Gilmour J; Stevens G; Smith MS; Tarragona-Fiol T; Hayes P; Kochhar S; Excler JL; Fast P
    AIDS Res Hum Retroviruses; 2009 Nov; 25(11):1107-16. PubMed ID: 19943789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults.
    Durier C; Launay O; Meiffrédy V; Saïdi Y; Salmon D; Lévy Y; Guillet JG; Pialoux G; Aboulker JP
    AIDS; 2006 Apr; 20(7):1039-49. PubMed ID: 16603857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 recombinant gp160 vaccine induced antibodies in serum and saliva. The NIAID AIDS Vaccine Clinical Trials Network.
    Gorse GJ; Rogers JH; Perry JE; Newman FK; Frey SE; Patel GB; Belshe RB
    Vaccine; 1995 Feb; 13(2):209-14. PubMed ID: 7625118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International clinical trials of HIV vaccines: II. phase I trial of an HIV-1 synthetic peptide vaccine evaluating an accelerated immunization schedule in Yunnan, China.
    Li D; Forrest BD; Li Z; Xue P; Hanson CV; Duan S; Cheng H; Li M; Wang CY; Koff WC
    Asian Pac J Allergy Immunol; 1997 Jun; 15(2):105-13. PubMed ID: 9346275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network.
    Belshe RB; Clements ML; Dolin R; Graham BS; McElrath J; Gorse GJ; Schwartz D; Keefer MC; Wright P; Corey L
    J Infect Dis; 1993 Dec; 168(6):1387-95. PubMed ID: 8245523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine.
    Mehendale S; van Lunzen J; Clumeck N; Rockstroh J; Vets E; Johnson PR; Anklesaria P; Barin B; Boaz M; Kochhar S; Lehrman J; Schmidt C; Peeters M; Schwarze-Zander C; Kabamba K; Glaunsinger T; Sahay S; Thakar M; Paranjape R; Gilmour J; Excler JL; Fast P; Heald AE
    AIDS Res Hum Retroviruses; 2008 Jun; 24(6):873-80. PubMed ID: 18544020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial.
    Baden LR; Karita E; Mutua G; Bekker LG; Gray G; Page-Shipp L; Walsh SR; Nyombayire J; Anzala O; Roux S; Laher F; Innes C; Seaman MS; Cohen YZ; Peter L; Frahm N; McElrath MJ; Hayes P; Swann E; Grunenberg N; Grazia-Pau M; Weijtens M; Sadoff J; Dally L; Lombardo A; Gilmour J; Cox J; Dolin R; Fast P; Barouch DH; Laufer DS;
    Ann Intern Med; 2016 Mar; 164(5):313-22. PubMed ID: 26833336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    Gorse GJ; Corey L; Patel GB; Mandava M; Hsieh RH; Matthews TJ; Walker MC; McElrath MJ; Berman PW; Eibl MM; Belshe RB
    AIDS Res Hum Retroviruses; 1999 Jan; 15(2):115-32. PubMed ID: 10029244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.
    Pialoux G; Excler JL; Rivière Y; Gonzalez-Canali G; Feuillie V; Coulaud P; Gluckman JC; Matthews TJ; Meignier B; Kieny MP
    AIDS Res Hum Retroviruses; 1995 Mar; 11(3):373-81. PubMed ID: 7598771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enrollment of racial/ethnic minorities in NIAID-funded networks of HIV vaccine trials in the United States, 1988 to 2002.
    Djomand G; Katzman J; di Tommaso D; Hudgens MG; Counts GW; Koblin BA; Sullivan PS
    Public Health Rep; 2005; 120(5):543-8. PubMed ID: 16224987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women.
    Cunningham CK; Wara DW; Kang M; Fenton T; Hawkins E; McNamara J; Mofenson L; Duliege AM; Francis D; McFarland EJ; Borkowsky W;
    Clin Infect Dis; 2001 Mar; 32(5):801-7. PubMed ID: 11229849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001).
    Baden LR; Walsh SR; Seaman MS; Tucker RP; Krause KH; Patel A; Johnson JA; Kleinjan J; Yanosick KE; Perry J; Zablowsky E; Abbink P; Peter L; Iampietro MJ; Cheung A; Pau MG; Weijtens M; Goudsmit J; Swann E; Wolff M; Loblein H; Dolin R; Barouch DH
    J Infect Dis; 2013 Jan; 207(2):240-7. PubMed ID: 23125444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.
    Pitisuttithum P; Gilbert P; Gurwith M; Heyward W; Martin M; van Griensven F; Hu D; Tappero JW; Choopanya K;
    J Infect Dis; 2006 Dec; 194(12):1661-71. PubMed ID: 17109337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group.
    McElrath MJ; Corey L; Montefiori D; Wolff M; Schwartz D; Keefer M; Belshe R; Graham BS; Matthews T; Wright P; Gorse G; Dolin R; Berman P; Francis D; Duliege AM; Bolognesi D; Stablein D; Ketter N; Fast P
    AIDS Res Hum Retroviruses; 2000 Jun; 16(9):907-19. PubMed ID: 10875616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.